RecruitingPhase 2NCT06524583

Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour

Studying Leiomyosarcoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
UNICANCER
Principal Investigator
Florence DUFFAUD, MD
La TIMONE University Hospital
Intervention
Doxorubicin(drug)
Enrollment
198 enrolled
Eligibility
18-75 years · FEMALE
Timeline
2025 – 2030

Study locations (25)

Collaborators

PharmaMar · Ligue contre le cancer, France · National Research Agency, France · University Hospital, Marseille · Institut Claudius Regaud · Institut Bergonié · Oncopole

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06524583 on ClinicalTrials.gov

Other trials for Leiomyosarcoma

Additional recruiting or active studies for the same condition.

See all trials for Leiomyosarcoma →

← Back to all trials